E-resources
Peer reviewed
-
Kozin, S. A.; Barykin, E. P.; Mitkevich, V. A.; Makarov, A. A.
Biochemistry (Moscow), 09/2018, Volume: 83, Issue: 9Journal Article
Drug development for the treatment of Alzheimer’s disease (AD) has been for a long time focused on agents that were expected to support endogenous β-amyloid (Aβ) in a monomeric state and destroy soluble Aβ oligomers and insoluble Aβ aggregates. However, this strategy has failed over the last 20 years and was eventually abandoned. In this review, we propose a new approach to the anti-amyloid AD therapy based on the latest achievements in understanding molecular causes of cerebral amyloidosis in AD animal models.
